
DBD Stock Forecast & Price Target
DBD Analyst Ratings
Bulls say
Diebold Nixdorf is projected to maintain its earnings growth through 2026/2027 thanks to strong execution, cost control measures, and visibility into margins. The company's well-stocked balance sheet allows for future investments and buybacks, in addition to its expansion into the U.S. market and partnerships with major retailers. With a positive outlook in North America, Europe, and Asia, DBD is recommended as a BUY with a strong financial standing and potential for further growth.
Bears say
Diebold Nixdorf is facing multiple risks such as potential tariff-related costs, disruptions in operations due to the COVID-19 pandemic and supply chain challenges, lower than expected activity in upgrade and replacement projects, and volatility in foreign currencies. The company also has low liquidity and high ownership concentration, with majority control in the hands of debtholders. While the company is expected to see sequential growth in the remainder of 2026, its current valuation and financials may not support a positive outlook.
This aggregate rating is based on analysts' research of Diebold Nixdorf Inc and is not a guaranteed prediction by Public.com or investment advice.
DBD Analyst Forecast & Price Prediction
Start investing in DBD
Order type
Buy in
Order amount
Est. shares
0 shares